Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by EbbandFlowon Mar 15, 2016 12:37am
237 Views
Post# 24658476

RE:Glad I sold out last week in the 0.20's

RE:Glad I sold out last week in the 0.20's
Jabookie75 wrote: For anyone buying this over 0.10 best of luck.  They have 55 million shares outstanding and now issued 50 million more at 0.10. For those coutning thatis about 90% dilution of the existing share count.  That is ridiculous.

Anyone buying in the 0.20's or God help us, 0.30 last week now have dead money on their hands. They still have to prove they can turn IDL arround and if they don't, they will burn through this $5 million in no time.  I will keep this on watch but when volume dies down and the crappy Q4 2015 and Q1 2016 numbers come in, this will drift lower.  It's going to take a few quarters for them to prove to the market that the turnaround is legit.  I am on the sidelines until that happens.

Not a basher.  Just a guy who has been involved with this company for the last year while they presided over one of the biggest declines I have ever seen.  From 2.00 to 0.01 tells the tale folks.  James Howard Tripp is a clown and has run this company into the ground.  I am still very skeptical of his ability to execute the turn around.  We shall see.


Ya im 100% on that with you, maybe they will invest this all into IDL then let genenews die off to then merger idl with another company, i do belive that they are tied into multiple companies, i dunno their wages and compensations but as of the members of board are probably topping (easily) the 300,000$ a year plus insentives, the person who financed the last chunk@ .32 i forget the name, i did look him up and is a billionaire. so .. that is odd , i doubt he would partake in a shady buisness. regardless i do hope they go big as cancer is serious and very real thing, to see these tech companies with a dumb iphone game go from 2mil to 50 mil yet a cancer research cant barely raise a dime. kinda sad. but its buisness. best luck to Genenews i will be watching closely 
Bullboard Posts